$NEPH
NEPHROS INC Stock $neph

$neph Overview Financials Valuation SEC Filings Company Website

2014 Q2 Form 10-Q Financial Statement

#000114420414050399 Filed on August 14, 2014

Income Statement

Concept	2014 Q2	2013 Q2
Revenue	$441.0K	$575.0K
YoY Change	-23.3%	90.4%
Cost Of Revenue	$142.0K	$226.0K
YoY Change	-37.17%	545.71%
Gross Profit	$299.0K	$349.0K
YoY Change	-14.33%	30.71%
Gross Profit Margin	67.8%	60.7%
Selling, General & Admin	$700.0K	$660.0K
YoY Change	6.06%	-21.24%
% of Gross Profit	234.11%	189.11%
Research & Development	$180.0K	$259.0K
YoY Change	-30.5%	30.15%
% of Gross Profit	60.2%	74.21%
Depreciation & Amortization	$120.0K	$10.00K
YoY Change	1100.0%	-75.0%
% of Gross Profit	40.13%	2.87%
Operating Expenses	$935.0K	$977.0K
YoY Change	-4.3%	-9.45%
Operating Profit	-$636.0K	-$628.0K
YoY Change	1.27%	-22.66%
Interest Expense	$17.00K	$24.00K
YoY Change	-29.17%
% of Operating Profit
Other Income/Expense, Net	-$1.000K	-$19.00K
YoY Change	-94.74%	-133.33%
Pretax Income	-$5.340M	-$670.0K
YoY Change	697.01%	-10.67%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$5.339M	-$1.279M
YoY Change	317.44%	69.63%
Net Earnings / Revenue	-1210.66%	-222.43%
Basic Earnings Per Share	-$0.21
Diluted Earnings Per Share	-$1.907M	-$408.5K
COMMON SHARES
Basic Shares Outstanding	25.17M shares
Diluted Shares Outstanding	25.17M shares

Balance Sheet

Concept	2014 Q2	2013 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$230.0K	$300.0K
YoY Change	-23.33%	-69.7%
Cash & Equivalents	$230.0K	$300.0K
Short-Term Investments
Other Short-Term Assets	$59.00K	$70.00K
YoY Change	-15.71%	-22.22%
Inventory	$163.0K	$147.0K
Prepaid Expenses
Receivables	$110.0K	$360.0K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$560.0K	$870.0K
YoY Change	-35.63%	-61.16%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.000K	$12.00K
YoY Change	-75.0%	-40.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.789M	$2.000M
YoY Change	-10.55%	-4.31%
Total Long-Term Assets	$1.792M	$2.012M
YoY Change	-10.93%	-4.64%
TOTAL ASSETS
Total Short-Term Assets	$560.0K	$870.0K
Total Long-Term Assets	$1.792M	$2.012M
Total Assets	$2.352M	$2.882M
YoY Change	-18.39%	-33.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.030M	$786.0K
YoY Change	31.04%	118.33%
Accrued Expenses	$233.0K	$200.0K
YoY Change	16.5%	17.65%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.684M	$1.689M
YoY Change	-0.3%	-30.78%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$450.0K	$350.0K
YoY Change	28.57%	-65.35%
Total Long-Term Liabilities	$450.0K	$350.0K
YoY Change	28.57%	-65.35%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.684M	$1.689M
Total Long-Term Liabilities	$450.0K	$350.0K
Total Liabilities	$2.136M	$2.041M
YoY Change	4.65%	-40.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$115.6M	-$107.9M
YoY Change	7.2%
Common Stock	$25.00K	$18.00K
YoY Change	38.89%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$216.0K	$841.0K
YoY Change
Total Liabilities & Shareholders Equity	$2.352M	$2.882M
YoY Change	-18.39%	-33.75%

Cashflow Statement

Concept	2014 Q2	2013 Q2
OPERATING ACTIVITIES
Net Income	-$5.339M	-$1.279M
YoY Change	317.44%	69.63%
Depreciation, Depletion And Amortization	$120.0K	$10.00K
YoY Change	1100.0%	-75.0%
Cash From Operating Activities	-$250.0K	-$1.630M
YoY Change	-84.66%	103.75%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00
YoY Change
Cash From Investing Activities		$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$3.000M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.680M
YoY Change	-100.0%	479.31%
NET CHANGE
Cash From Operating Activities	-250.0K	-1.630M
Cash From Investing Activities		0.000
Cash From Financing Activities	0.000	1.680M
Net Change In Cash	-250.0K	50.00K
YoY Change	-600.0%	-104.24%
FREE CASH FLOW
Cash From Operating Activities	-$250.0K	-$1.630M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	18000	USD
CY2014Q2	us-gaap	Cash Cash	225000	USD
CY2014Q2	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	113000	USD
CY2014Q2	us-gaap	Inventory Net InventoryNet	163000	USD
CY2014Q2	us-gaap	Assets Current AssetsCurrent	560000	USD
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3000	USD
CY2014Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1789000	USD
CY2014Q2	us-gaap	Assets Assets	2352000	USD
CY2014Q2	neph	Senior Secured Note Payable Net Of Discount SeniorSecuredNotePayableNetOfDiscount	0	USD
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	1684000	USD
CY2014Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	233000	USD
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	421000	USD
CY2014Q2	us-gaap	Other Assets Current OtherAssetsCurrent	59000	USD
CY2013Q4	neph	Senior Secured Note Payable Net Of Discount SeniorSecuredNotePayableNetOfDiscount	1358000	USD
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1073000	USD
CY2014Q2	us-gaap	Liabilities Liabilities	2136000	USD
CY2013Q4	us-gaap	Liabilities Liabilities	3499000	USD
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	25000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	74000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101228000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-610000	USD
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2889000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2100000	USD
CY2014Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	102761000	USD
CY2013Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	100526000	USD
CY2014Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	72000	USD
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-102642000	USD
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	216000	USD
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	2352000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <strong>Use of Estimates</strong></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; TEXT-INDENT: 29.7pt; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-ALIGN: justify; MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. <font style="LINE-HEIGHT: 115%; FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"> The more significant estimates used by management relate to the valuation of inventory reserves and the measurement of deferred revenue.</font> Actual results could differ materially from those estimates.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2014Q1	neph	Upfront Fees And Connection Of First Amendment UpfrontFeesAndConnectionOfFirstAmendment	225000	EUR
CY2014Q2	neph	Upfront Fees And Connection Of First Amendment UpfrontFeesAndConnectionOfFirstAmendment	225000	EUR
CY2014Q2	us-gaap	Deferred Revenue DeferredRevenue	873000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q2	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	92000	USD
CY2013Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	365000	USD
CY2013Q4	neph	Note Payable Net Of Discount NotePayableNetOfDiscount	142000	USD
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	90000000	shares
CY2014Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25226104	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18082043	shares
CY2014Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25226104	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18082043	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	206000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	224000	USD
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	302519	shares
CY2014Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	674000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y1M6D
	us-gaap	Share Based Compensation ShareBasedCompensation	3000	USD
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Current Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInCurrentYear	0.28	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In One Year ExpectedRecognitionOfUnrecognizedCompensationCostsDueInOneYear	0.55	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Two Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInTwoYears	0.15	pure
	neph	Expected Recognition Of Unrecognized Compensation Costs Due In Three Years ExpectedRecognitionOfUnrecognizedCompensationCostsDueInThreeYears	0.02	pure
	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	127000	USD
	neph	Warrants Exercised WarrantsExercised	70147	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	3238	shares
	neph	Class Of Warrant Or Rights Exercisable ClassOfWarrantOrRightsExercisable	11742100	shares
CY2014Q2	us-gaap	Inventory Gross InventoryGross	255000	USD
CY2013Q4	us-gaap	Inventory Gross InventoryGross	527000	USD
	neph	Repayments Of Accrued Interest On Senior Secured Note RepaymentsOfAccruedInterestOnSeniorSecuredNote	61000	USD
CY2014Q1	neph	Authorized Value Of Rights Offering AuthorizedValueOfRightsOffering	2800000	USD
CY2014Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.28673	shares
CY2014Q1	neph	Class Of Warrant Or Right Issued Gross Value Received ClassOfWarrantOrRightIssuedGrossValueReceived	2100000	USD
CY2014Q1	neph	Class Of Warrant Or Right Issued Net Value Received ClassOfWarrantOrRightIssuedNetValueReceived	581000	USD
	neph	Repayments Of Senior Secured Note RepaymentsOfSeniorSecuredNote	1500000	USD
CY2014Q2	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	120000	USD
	neph	Reimbursement Of Legal Fee ReimbursementOfLegalFee	75000	USD
	neph	Percentage Of Total Shares Offered In Rights Offering PercentageOfTotalSharesOfferedInRightsOffering	0.77	pure
CY2014Q2	us-gaap	Accumulated Amortization Of Other Deferred Costs AccumulatedAmortizationOfOtherDeferredCosts	462000	USD
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	105000	USD
	neph	Royalty Rate RoyaltyRate	0.03	pure
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	105000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	210000	USD
CY2014Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	212000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	737000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	467000	USD
CY2013Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	391000	USD
CY2014Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	248000	USD
	us-gaap	Licenses Revenue LicensesRevenue	359000	USD
	us-gaap	Licenses Revenue LicensesRevenue	448000	USD
CY2013Q2	us-gaap	Licenses Revenue LicensesRevenue	184000	USD
CY2014Q2	us-gaap	Licenses Revenue LicensesRevenue	193000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	1096000	USD
	us-gaap	Sales Revenue Net SalesRevenueNet	915000	USD
CY2013Q2	us-gaap	Sales Revenue Net SalesRevenueNet	575000	USD
CY2014Q2	us-gaap	Sales Revenue Net SalesRevenueNet	441000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	421000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	248000	USD
CY2013Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	226000	USD
CY2014Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	142000	USD
	us-gaap	Gross Profit GrossProfit	675000	USD
	us-gaap	Gross Profit GrossProfit	667000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	349000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	299000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	483000	USD
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	343000	USD
CY2013Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	259000	USD
CY2014Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	180000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	114000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	110000	USD
CY2013Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	58000	USD
CY2014Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	55000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1714000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	1412000	USD
CY2013Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	660000	USD
CY2014Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	700000	USD
	us-gaap	Operating Expenses OperatingExpenses	2311000	USD
	us-gaap	Operating Expenses OperatingExpenses	1865000	USD
CY2013Q2	us-gaap	Operating Expenses OperatingExpenses	977000	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	935000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1636000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1198000	USD
CY2013Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-628000	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-636000	USD
	us-gaap	Interest Expense InterestExpense	47000	USD
	us-gaap	Interest Expense InterestExpense	70000	USD
CY2013Q2	us-gaap	Interest Expense InterestExpense	24000	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	17000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	2000	USD
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2013Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014Q2	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	204000	USD
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	142000	USD
CY2013Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
CY2014Q2	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-27000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4000	USD
CY2013Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-19000	USD
CY2014Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1912000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-1414000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-671000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-654000	USD
CY2012Q4	us-gaap	Cash Cash	47000	USD
CY2013Q2	us-gaap	Cash Cash	298000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
CY2013Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-2000	USD
CY2014Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-1000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1914000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1416000	USD
CY2013Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-673000	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-655000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.14
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.06
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.05
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.03
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13289703	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	22004712	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	14556050	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	25166752	shares
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-2000	USD
	neph	Stock Issued During Period Value Shareholder Rights Offering StockIssuedDuringPeriodValueShareholderRightsOffering	2013000	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments	2000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	227000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	109000	USD
	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	105000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	248000	USD
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	227000	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	0	USD
	neph	Inventory Fifo Reserve Period Charge InventoryFifoReservePeriodCharge	31000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-3000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-4000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-577000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-9000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-166000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	32000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-37000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-66000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-316000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-180000	USD
	neph	Increase Decrease In License And Supply Agreement Fee Payable IncreaseDecreaseInLicenseAndSupplyAgreementFeePayable	-1318000	USD
	neph	Increase Decrease In License And Supply Agreement Fee Payable IncreaseDecreaseInLicenseAndSupplyAgreementFeePayable	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-359000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	170000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-2558000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-867000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	2000	USD
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	2000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2771000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	2013000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	1300000	USD
	us-gaap	Proceeds From Issuance Of Senior Long Term Debt ProceedsFromIssuanceOfSeniorLongTermDebt	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	239000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1300000	USD
	us-gaap	Repayments Of Senior Debt RepaymentsOfSeniorDebt	1500000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	204000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	0	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	2806000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	515000	USD
	neph	Restricted Stock Shares Issued To Settle Liability RestrictedStockSharesIssuedToSettleLiability	0	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-2000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	251000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-354000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	2000	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	4000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	229000	USD
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	128000	USD
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2014-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Registrant Name EntityRegistrantName	NEPHROS INC
	dei	Entity Central Index Key EntityCentralIndexKey	0001196298
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	NEPH
CY2014Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25247120	shares
	neph	Restricted Stock Shares Issued To Settle Liability RestrictedStockSharesIssuedToSettleLiability	77000	USD
	neph	Accrued Royalty Payments AccruedRoyaltyPayments	4000	USD
CY2014Q2	neph	Filtration Product Sales Net FiltrationProductSalesNet	148000	USD
	neph	Percentage Of Sourcing Fees PercentageOfSourcingFees	0.08	pure
CY2014Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.30
CY2014Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.30
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	452000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	0	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif"> <b>1.  Organization and Nature of Operations</b></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">Nephros, Inc. (“Nephros” or the “Company”) was incorporated under the laws of the State of Delaware on April 3, 1997. Nephros was founded by health professionals, scientists and engineers affiliated with Columbia University to develop advanced End Stage Renal Disease (“ESRD”) therapy technology and products. The Company has two products in the hemodiafiltration, or HDF, modality to deliver therapy for ESRD patients. These are the OLpūr mid-dilution HDF filter or “dialyzer,” designed expressly for HDF therapy, and the OLpūr H2H HDF module, an add-on module designed to allow the most common types of hemodialysis machines to be used for HDF therapy. In 2009, the Company introduced its Dual Stage Ultrafilter (“DSU”) water filter, which represented a new and complementary product line to the Company’s ESRD therapy business. The DSU incorporates the Company’s unique and proprietary dual stage filter architecture.</div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif">  </div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif" align="justify">On June 4, 2003, Nephros International Limited was incorporated under the laws of Ireland as a wholly-owned subsidiary of the Company.  In August 2003, the Company established a European Customer Service and financial operations center in Dublin, Ireland.</div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
	us-gaap	Interest Paid InterestPaid	24000	USD
	us-gaap	Interest Paid InterestPaid	54000	USD
	neph	Right Offering Fee Amount RightOfferingFeeAmount	128000	USD
	neph	Upfront Fees And Connection Of First Amendment UpfrontFeesAndConnectionOfFirstAmendment	450000	EUR
	neph	Upfront Fees And Connection Of First Amendment UpfrontFeesAndConnectionOfFirstAmendment	612000	USD

Files In Submission

Name	View Source	Status
0001144204-14-050399-index-headers.html	Edgar Link	pending
0001144204-14-050399-index.html	Edgar Link	pending
0001144204-14-050399.txt	Edgar Link	pending
0001144204-14-050399-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
neph-20140630.xml	Edgar Link	completed
neph-20140630.xsd	Edgar Link	pending
neph-20140630_cal.xml	Edgar Link	unprocessable
neph-20140630_def.xml	Edgar Link	unprocessable
neph-20140630_lab.xml	Edgar Link	unprocessable
neph-20140630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v383305_10q.htm	Edgar Link	pending
v383305_ex31-1.htm	Edgar Link	pending
v383305_ex32-1.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NEPH
NEPHROS INC Stock $neph

2014 Q2 Form 10-Q Financial Statement

#000114420414050399 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH NEPHROS INC Stock $neph

2014 Q2 Form 10-Q Financial Statement

#000114420414050399 Filed on August 14, 2014

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NEPH
NEPHROS INC Stock $neph